Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolvaptan (Primary)
Indications Heart failure; Hyponatraemia
Focus Therapeutic Use

Most Recent Events

23 Jul 2020 Status changed from recruiting to discontinued due to low accrual rate.
15 May 2019 Planned End Date changed from 1 Oct 2019 to 1 Nov 2020.
15 May 2019 Planned primary completion date changed from 1 Mar 2019 to 1 May 2020.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight